The sale is pre-planned under a 10b5-1 plan and represents a small portion of the CEO's holdings. No immediate bearish signal; monitor for any acceleration of insider selling or changes to the plan.
QURE drugs
QURE drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Jun 25 $49.10entry
- T+1 · 5mo ago −3.24%α −2.52% · $47.51
- T+5 · 5mo ago −8.00%α −9.56% · $45.17
- T+20 · 4mo ago −19.69%α −20.22% · $39.43
- T+60 · due 8w ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CEO Matthew C. Kapusta filed a Form 144 notice of intent to sell 6,696 ordinary shares valued at approximately $334,800. The shares stem from vested PSU/RSU positions and a stock option exercise, with sales to occur under a 10b5-1 plan adopted in October 2025. This is a routine, pre-planned sale by the CEO, not a discretionary insider sale, and represents a small fraction of his total holdings.
Key Facts
- CEO Matthew C. Kapusta filed Form 144 to sell 6,696 ordinary shares.
- Estimated aggregate value of proposed sale: $334,800.
- Shares originate from vested PSU/RSU positions and a stock option exercise.
- Sale is conducted under a 10b5-1 trading plan adopted in October 2025.
- Kapusta's total holdings (including recent acquisitions) are substantial, with recent positions valued over $9.2M.
- Filing date: June 24, 2026.
Financial Impact
Proposed sale of 6,696 shares (~$334,800) is small relative to CEO's total holdings and company's $3.1B market cap.
Risk Factors
- CEO selling even under a plan could be perceived negatively by some market participants.
- If the company's stock price declines, the sale may be executed at lower prices, but this is a pre-planned trade.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001973379-26-000252 |
| Document: 0001973379-26-000252-index.html | 0001973379-26-000252 |
| Document: 0001973379-26-000252.txt | 0001973379-26-000252 |
Track record
38 reports on QURE
6 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +27.15% at T+20 after the Jul 29, 2026 report. 8 of 11 went positive at some point.
Filters
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $22.79 to $22.71 Now $21.88 −3.99% ▼ −0.35% +0.02% vs SPY
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 6/10 Entry $23.03 to $21.01 Now $21.88 −4.99% ▼ −8.77% −4.36% vs SPY
- Nov 2, 202614d ago 8-K Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Nov 2, 202614d ago Press Release Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Oct 16, 20264w ago SC 13G/A Neutral 3/10 Entry $21.78 to $22.20 Now $21.88 +0.46% ▲ +1.93% +1.51% vs SPY
- Sep 2, 202610w ago 8-K Bullish 7/10 Entry $46.23 to $44.86 Now $21.88 −52.67% ▼ −2.96% −4.01% vs SPY
- Jul 29, 202615w ago 8-K Bullish 8/10 Entry $40.07 to $42.19 Now $21.88 −45.40% ▲ +5.29% +3.61% vs SPY
- Jul 7, 202619w ago Insider Cluster Bearish 5/10 Entry $41.41 to $43.49 Now $21.88 +47.16% ▼ −5.02% −5.33% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 4/10 Entry $41.81 to $41.36 Now $21.88 +47.67% ▲ +1.08% +1.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers